Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States

Patient Preference and Adherence

Volumn 10, Issue , 2016, Pages 45-55

  Boklage, Susan H ^a   Mangel, Allen W ^b   Ramamohan, Varun ^b   Mladsi, Deirdre ^b   Wang, Tao ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cost effectiveness; Fecal antigen test; Helicobacter pylori; Noninvasive diagnostic testing; Serology; Urea breath test

Indexed keywords

ANTIGEN DETECTION; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; HEALTH CARE COST; HELICOBACTER INFECTION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; NON INVASIVE PROCEDURE; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SEROLOGY; STOMACH CANCER; UNITED STATES; UREA BREATH TEST;

EID: 84957884791     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S93320     Document Type: Article

References (37)

1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825.
2. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175:54–59.
3. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–490.
4. Peterson WL, Fendrick M, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med. 2000;160:1285–1291.
5. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol. 2006;3:80–89.
6. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129:1753–1755.
7. Chey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the “test-and-treat” strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med. 2001;161:2129–2132.
8. Elwyn G, Taubert M, Davies S, Brown G, Allison M, Phillips C. Which test is best for Helicobacter pylori? A cost-effectiveness model using decision analysis. Br J Gen Pract. 2007;57:401–403.
9. Holmes KP, Fang JC, Jackson BR. Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Serv Res. 2010;10:344.
10. Masucci L, Blackhouse G, Goeree R. Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis. Ont Health Technol Assess Ser. 2013;13:1–28.
11. Vakil N, Rhew D, Soll A, Ofman JJ. The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori. Am J Gastroenterol. 2000;95:1691–1698.
12. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter. 2004;9:347–368.
13. Cullen KP, Broderick BM, Jayaram J, Flynn B, O’Connor HJ. Evaluation of the Helicobacter pylori stool antigen (HpSA) test in routine clinical practice – is it patient-friendly? Ir Med J. 2002;95:305–306.
14. McNulty CA, Whiting JW. Patients’ attitudes to Helicobacter pylori breath and stool antigen tests compared to blood serology. J Infect. 2007;55:19–22.
15. Ore L, Hagoel L, Lavi I, Rennert G. Screening with faecal occult blood test (FOBT) for colorectal cancer: assessment of two methods that attempt to improve compliance. Eur J Cancer Prev. 2001;10:251–256.
16. Gisbert JP, Pajares JM. 13C-urea breath test in the diagnosis of Helicobacter pylori infection – a critical review. Aliment Pharmacol Ther. 2004;20:1001–1017.
17. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol. 1996;91:1138–1144.
18. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–609.
19. Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol. 2006;163:127–134.
20. Arias E, Curtin LR, Wei R, Anderson RN. U.S. decennial life tables for 1999–2001, United States life tables. Natl Vital Stat Rep. 2008;57:1–36.
21. Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008;13:56–61.
22. Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014;2:210.
23. Ghanouni A, Smith SG, Halligan S, et al. Public preferences for colorectal cancer screening tests: a review of conjoint analysis studies. Expert Rev Med Devices. 2013;10:489–499.
24. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797.
25. OptumInsight. The Essential RBRVS 2014: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Eden Prairie (MN): OptumInsight; 2014.
26. Truven Health Analytics. Red Book. 2014. Available from: http://micromedex.com/redbook. Accessed December 13, 2015.
27. Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther. 1999;13 Suppl 1:3–11.
28. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 1998;129:547–550.
29. Davies R, Crabbe D, Roderick P, Goddard JR, Raftery J, Patel P. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci. 2002;5:249–258.
30. Asaka M, Sepulveda AR, Sugiyama T, Graham DY. Gastric cancer. In: Mobley HL, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington: American Society for Microbiology Press; 2001.
31. Chiba N, van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 2002;324:1012–1016.
32. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer. 2010;116:2941–2953.
33. Howard K, Lord SJ, Speer A, Gibson RN, Padbury R, Kearney B. Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies. Int J Technol Assess Health Care. 2006;22:109–118.
34. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med. 2004;32:1277–1283.
35. You JH, Tsui KK, Wong RS, Chang G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One. 2012;7:e39640.
36. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630–641.
37. Slawsky K, Cyr PL, Olchanski N, Howden CW. Cost-effectiveness of diagnostic strategies for H. pylori infection in a high prevalence population. Gastroenterology. 2011;140 Suppl 1:S203.